Skip to main content

Table 7 Possibly and probably related adverse events leading to discontinuation of study drug (overall period)

From: Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study

Treatment at time of event

Patient

MedDRA preferred term

Intensity

Serious

Causality

Outcome

First period IVIg

Patient 1

Muscle spasms

Severe

Yes

Probable

Recovered/resolved

Sinus tachycardia

Moderate

No

Probable

Recovered/resolved

Chills

Mild

No

Probable

Recovered/resolved

Fever

Mild

No

Probable

Recovered/resolved

Dyspnoea

Severe

Yes

Probable

Recovered/resolved

Back pain

Moderate

No

Probable

Recovered/resolved

Extension period (all IVIg)

Patient 2

Deep vein thrombosis (TEE)

Severe

Yes

Probable

Recovered/resolved

Pulmonary embolism (TEE)

Severe

Yes

Probable

Recovered/resolved

Patient 3

Vertigo

Moderate

No

Possible

Recovered/resolved

Vision blurred

Mild

No

Possible

Recovered/resolved

Cerebrovascular accident (TEE)

Moderate

Yes

Possible

Recovered/resolved with sequelae

Patient 4

Pulmonary embolism (TEE)

Moderate

Yes

Possible

Recovered/resolved with sequelae

Patient 8

Musculoskeletal pain

Mild

No

Possible

Recovered/resolved

Paraesthesia

Mild

No

Possible

Recovered/resolved

Dizziness

Mild

No

Possible

Recovered/resolved

Condition aggravateda

Mild

No

Not related

Recovered/resolved

Patient 9

Headache

Moderate

No

Probable

Recovered/resolved

Nausea

Moderate

No

Probable

Recovered/resolved

Patient 10

Hypersensitivity

Mild

No

Probable

Recovered/resolved

Patient 11

Vomiting

Mild

No

Probable

Recovered/resolved

  1. aAssessed as unrelated to study drug but included for completeness of information for patient 8. IVIg Intravenous immunoglobulin, MedDRA Medical dictionary for regulatory activities, TEE Thromboembolic event